EMEA-001832-PIP01-15-M02 - paediatric investigation plan
glecaprevir
pibrentasvir
PIPHuman
AbbVie Ltd
E-mail: paediatricteam@abbvie.com
Tel. +44(0) 1628925033
P/0128/2019: EMA decision of 17 April 2019 on the acceptance of a modification of an agreed paediatric investigation plan for glecaprevir / pibrentasvir (Maviret) (EMEA-001832-PIP01-15-M02)